2009至2018年透析治疗的急性肾损伤特征与结局:台湾多中心研究
该研究为台湾多中心回顾性队列,纳入2009至2018年9,535例首次接受透析的成人ICU患者,发现透析启动时平均SOFA评分从14.0略降至13.6,ICU死亡率从56.1%降至2015年46.3%后略升,调整后2013至2018年死亡风险显著低于2009年,存活者出院时透析比例从36.8%升至43.9%。
要点
- 透析启动时平均SOFA评分从2009年14.0略降至2018年13.6
- ICU死亡率从2009年56.1%降至2015年46.3%后略升
- 调整后2013至2018年死亡风险显著低于2009年
核心结论
- 2009至2018年ICU透析治疗AKI患者死亡率下降,调整透析指征与疾病严重度后仍显著。
- 存活者出院时透析比例随时间增加,主要用于估算肾小球滤过率<60mL/min/1.73m2者。
研究设计与样本
- 多中心回顾性队列研究。
- 纳入2009至2018年台湾长庚纪念医院系统9,535例首次接受透析的成人ICU患者。
- 暴露为日历年,结局为ICU死亡和出院时透析。
主要发现
- 透析启动时平均SOFA评分从2009年14.0略降至2018年13.6。
- 满足透析指征的数量随时间无显著趋势。
- ICU死亡率从2009年56.1%降至2015年46.3%,之后略升,呈反向J形曲线。
- 调整后2013至2018年死亡风险显著低于2009年,且下降趋势持续显著。
- 存活者出院时透析比例从2009年36.8%升至2018年43.9%,主要用于eGFR<60mL/min/1.73m2者。
局限性
- 随时间变化的未测量因素如合并症严重度、详细药物干预和透析剂量可致残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Dialysis-treated acute kidney injury (AKI) is increasingly common in intensive care units (ICUs) and is associated with poor outcomes. Few studies have explored the temporal trends in severity of acute illness at dialysis initiation, indications for dialysis, and their association with patient outcomes. STUDY DESIGN: Multicenter retrospective cohort study. SETTING & PARTICIPANTS: 9,535 adult patients admitted to the ICU who received their first dialysis treatment from Chang Gung Memorial Hospital system in Taiwan from 2009 through 2018. EXPOSURE: Calendar year. OUTCOMES: ICU mortality and dialysis treatment at discharge among hospital survivors. ANALYTICAL APPROACH: The temporal trends during the study period were investigated using test statistics suited for continuous or categorical data. The association between the study year and the risk of mortality was analyzed using multivariable Cox regression with adjustment for relevant clinical variables, including the severity of acute illness, defined by Sequential Organ Failure Assessment (SOFA) score. RESULTS: The mean SOFA score at dialysis initiation decreased slightly from 14.0 in 2009 to 13.6 in 2018. There was no significant trend in the number of indications for dialysis initiation that were fulfilled over time. Observed ICU mortality decreased over time, and the curve appeared to be reverse J-shaped, with a substantial decrease from 56.1% in 2009 to 46.3% in 2015 and a slight increase afterward. The risk of mortality was significantly reduced from 2013 to 2018 compared with 2009 in adjusted models. The decreasing trend in ICU mortality over time remained significant. There was an increase in dialysis treatment at discharge among survivors, mainly in patients with estimated glomerular filtration rate<60mL/min/1.73m2, from 36.8% in 2009 to 43.9% in 2018. LIMITATIONS: Residual confounding from unmeasured factors over time such as severity of comorbidities, detailed medication interventions, and delivered dialysis dose. CONCLUSIONS: We observed reductions in mortality among ICU patients with dialysis-treated acute kidney injury between 2009 and 2018, even after adjusting for dialysis indication and severity of illness at dialysis initiation. However, dialysis treatment at discharge among survivors has increased over time, mainly in patients with preexisting kidney disease. PLAIN-LANGUAGE SUMMARY: The current medical management of severe acute kidney injury (AKI) is primarily limited to supportive care and kidney replacement therapy if indicated, leading to perceptions that outcomes among intensive care unit (ICU) patients with dialysis-treated AKI have not improved. In this multicenter retrospective study of ICU patients with dialysis-treated AKI between 2009 and 2018 in Taiwan, patient mortality decreased over time despite increasing comorbidities. Moreover, the decreasing linear trends remained significant even when considering severity of acute illness at dialysis initiation, which was based on physiologic and laboratory measurements seldom evaluated in previous studies. Further research should explore the basis for these improvements.
引用
- Lee CC, Kuo G, Chan MJ, et al. Characteristics of and Outcomes After Dialysis-Treated Acute Kidney Injury, 2009-2018: A Taiwanese Multicenter Study. Am J Kidney Dis. 2022. PMID: 36252882. doi:10.1053/j.ajkd.2022.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。